dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Stathakis, N. | en |
dc.contributor.author | Alexopoulos, C. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Constantinidou, M. | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Papageorgiou, E. | en |
dc.contributor.author | Dervenoulas, John | en |
dc.contributor.author | Pappa, Vassiliki | en |
dc.contributor.author | Vaslamatzis, M. | en |
dc.contributor.author | Raptis, S. | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Stathakis, N. | en |
dc.creator | Alexopoulos, C. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Constantinidou, M. | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Papageorgiou, E. | en |
dc.creator | Dervenoulas, John | en |
dc.creator | Pappa, Vassiliki | en |
dc.creator | Vaslamatzis, M. | en |
dc.creator | Raptis, S. | en |
dc.date.accessioned | 2018-06-22T09:52:56Z | |
dc.date.available | 2018-06-22T09:52:56Z | |
dc.date.issued | 1994 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41574 | |
dc.description.abstract | The risk and the type of second malignancies (SM) developing in 217 treated Hodgkin's disease (HD) patients were studied. The median age of the patients was 35 years (range 14-83) and the M/F ratio 1.8. Treatment consisted of radiotherapy alone (24 patients, 11%), chemotherapy alone (96 patients, 44.3%), or a combination of both modalities (43 patients, 19.8%), while 54 patients (24.9%) received salvage treatment. The median follow-up time was 67 months (range 12-224). Ten patients developed a SM with a 5-year and 10-year actuarial risk of 3.3% and 5.4%, respectively. There were 3 cases of ANLL and MDS (actuarial risk of 2.4% at 6 years), 1 case of non-Hodgkin's lymphoma and 6 cases of solid tumors (actuarial risk of 3.2% at 10 years). The risk of developing SM was higher in males and older patients (>40 years). SM represent a serious late side effect of successful treatment for HD. The possibility of developing a SM must be taken into consideration in the initial treatment of the disease. | en |
dc.language.iso | eng | en |
dc.source | Haematologica | en |
dc.subject | Greece | en |
dc.subject | Article | en |
dc.subject | Bleomycin | en |
dc.subject | Chlormethine | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Dacarbazine | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Prednisone | en |
dc.subject | Procarbazine | en |
dc.subject | Vinblastine | en |
dc.subject | Vincristine | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Adolescent | en |
dc.subject | Lomustine | en |
dc.subject | Male | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Follow-up studies | en |
dc.subject | Nitrosourea derivative | en |
dc.subject | Chlorambucil | en |
dc.subject | Hodgkin disease | en |
dc.subject | Hodgkin's disease | en |
dc.subject | Myelodysplastic syndrome | en |
dc.subject | Second cancer | en |
dc.subject | Second malignancies | en |
dc.subject | Second primary | en |
dc.subject | Treatment | en |
dc.title | Second malignancies following treatment for Hodgkin's disease: A Greek experience | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 79 | |
dc.description.issue | 3 | |
dc.description.startingpage | 273 | |
dc.description.endingpage | 276 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Dervenoulas, John [0000-0001-8395-507X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0001-8395-507X | |